Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands

IUBMB Life. 2016 Mar;68(3):173-7. doi: 10.1002/iub.1475. Epub 2016 Jan 27.

Abstract

Glioblastoma multiforme (GBM), also known as glioblastoma, is the most common and aggressive brain tumor. GBM has a poor survival rate and high resistance to standard therapy, leading to recurrence and metastasis to adjacent normal regions. Glioblastoma stem cells (GSCs) are regarded as an emerging target for therapy of GBM. Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that functions in a variety of cancers and in normal adipocyte differentiation. The newly discovered connection between PPARγ ligands and cancer stem cells (CSCs) raises important implications for the potential therapeutic use of synthetic PPARγ ligands, such as thiazolidinediones (TZDs), in glioblastoma. Here, I hypothesize that synthetic PPARγ ligands serve to modulate stemness-related molecules and several signaling pathway in GSCs and I propose potential experimental approaches to investigate the effects of these ligands on GSCs in vitro and in vivo.

Keywords: PPARγ ligands; cancer stem cells; glioblastoma multiforme; thiazolidinediones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Brain Neoplasms / drug therapy*
  • Drug Screening Assays, Antitumor
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glioblastoma / drug therapy*
  • Humans
  • Ligands
  • Neoplastic Stem Cells / drug effects*
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Signal Transduction
  • Thiazolidinediones / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Ligands
  • PPAR gamma
  • Thiazolidinediones